# GI Windows

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gi-windows

- Industry: Healthcare
- Headquarters: Westwood, US
- Website: www.giwindows.com
- Total disclosed funding: $68M
- Latest round: Series B (Nov 20, 2024)
- Investors on record: 8

## About

GI Windows, Inc. is a US-based company specializing in advanced anastomotic technologies that enhance surgical procedures through innovative medical devices, aimed at improving patient outcomes and operational efficiency.Founded in 2012 in Westwood, US, GI Windows, Inc. focuses on developing medical devices to improve surgical anastomosis. The company has successfully completed 4 deals, with the latest funding round, a Series B, occurring on November 20, 2024. This round raised USD 37 mn and was led by Orlando Health Ventures, with participation from other notable investors such as Johnson & Johnson Innovation and J.C. Investments, LLC. The company was co-founded by Christopher Thompson and Marvin Ryou, with Brian Tinkham currently serving as the CEO.GI Windows Surgical specializes in pioneering anastomotic technologies aimed at enhancing surgical procedures through less invasive methods. Their core product offerings include innovative medical devices such as Flexagon™ and OTOLoc™, both designed to facilitate surgical anastomosis with improved efficiency and safety for surgeons and patients alike. These technologies address critical use cases in various surgical environments, targeting needs such as faster recovery times and reduced complications during and after surgery. The company’s solutions primarily cater to healthcare providers, including hospitals and surgical clinics, particularly in regions such as North America and Europe, where advanced surgical techniques are increasingly in demand.GI Windows Surgical's revenue model is focused on B2B transactions, predominantly involving healthcare institutions and surgical facilities as their primary clients. The company engages in direct sales of its flagship products, Flexagon™ and OTOLoc™, which are positioned as innovative solutions for surgical applications. Transactions are facilitated through contractual agreements with healthcare providers who purchase these devices as part of their surgical toolkits. The pricing structure for these medical devices is established based on the value they deliver in terms of improved surgical outcomes, though specific pricing details are not disclosed. This strategic approach emphasizes partnerships with medical professionals and institutions that leverage the company's technology to enhance patient care.In November 2024, GI Windows, Inc. raised USD 37 mn in Series B funding, led by Orlando Health Ventures, to support the development of its medical products. The company plans to utilize this funding to enhance its innovative offerings and may introduce new products designed to further improve surgical procedures. Additionally, GI Windows is looking to expand its market reach into new geographic regions, with specific targets in additional European markets by the end of 2025.

## Funding rounds

- Series B, Nov 20, 2024, $37M — Johnson & Johnson Innovation, Rex Health Ventures, Orlando Health Ventures, J.C. Investments, LLC
- Series A, Aug 19, 2020, $16M — Johnson & Johnson Innovation, GT Healthcare Capital Partners, Sonder Capital, J.C. Investments, LLC, The Kennedy Trust, The Coleman Charitable Trust
- Series A, Dec 11, 2019, $15M — GT Healthcare Capital Partners, Sonder Capital

## Investors

- GT Healthcare Capital Partners (https://capitalatlas.ai/funds/gt-healthcare-capital-partners) — Series A
- Sonder Capital (https://capitalatlas.ai/funds/sonder-capital) — Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B
- J.C. Investments, LLC — Series A, Series B
- The Kennedy Trust (https://capitalatlas.ai/funds/the-kennedy-trust) — Series A
- The Coleman Charitable Trust — Series A
- Rex Health Ventures (https://capitalatlas.ai/funds/rex-health-ventures) — Series B
- Orlando Health Ventures — Series B